Population pharmacokinetics of survodutide in subjects with overweight or obesity with and without Type 2 Diabetes Mellitus based on Phase I and Phase II data PAGE 32 (2024) Abstr 11127 Smania G, Glatard A, Bergstrand M, Schmid B, Retlich S, Wojtyniak JG. ConferenceMetabolicPharmacometricsTrial design and analysis Pharmetheus Affiliates Principal Director, MIDD Consultant Giovanni Smania See bio Senior Director, MIDD Consultant Anaïs Glatard See bio Principal Director, MIDD Scientific Lead Martin Bergstrand See bio